
mAbNews
European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer
03/31/2021
The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB
03/25/2021
Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]
ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab
02/15/2021
They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix